Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma

Masatoshi Kudo

doi:10.21037/hbsn-22-143

Back

Shared by

Masatoshi Kudo

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma

Editorial Material 2022 en

Authors

Masatoshi Kudo

Related publications

Article2022

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, Stephen L. Chan, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Yuriy Ostapenko,

Discussion(0)

Sign in to like and join the discussion.

No comments yet. Be the first to comment.

Thomas Yau,

Sérgio Jobim Azevedo,

Marı́a Varela,

Ann‐Lii Cheng,

Shukui Qin,

Peter R. Galle,

Sajid Ali,

Michelle Marcovitz,

Mallory Makowsky,

Philip He,

John F. Kurland,

Alejandra Negro,

Bruno Sangro

Editorial Material2022

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

Article2024

Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice

Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hideko Ohama, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Fujimasa Tada, Shinichiro Nakamura, Yoshiko Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Hironori Tanaka, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada

Article2025

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis

Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Hiroki Nishikawa, Kazunari Tanaka, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Yuichi Koshiyama, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake, Hideko Ohama, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Takashi Nishimura, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Tomoko Aoki, Hidekatsu Kuroda, Yutaka Yata, Hideyuki Tamai, Takanori Matsuura, Shohei Komatsu, Yoshihide Ueda, Yoshiko Nakamura, Osamu Yoshida, Kosuke Matsui, Shinichiro Nakamura, Hirayuki Enomoto, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo

Article2023

Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)

Marie‐Luise Berres, Stephen L. Chan, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, Junji Furuse, Joong‐Won Park, Patrapim Sunpaweravong, Angelica Fasolo, Thomas Yau, Tomokazu Kawaoka, Ann-Li Cheng, Sérgio Santos de Azevêdo, María Reig, Éric Assenat, Mark Yarchoan, Aiwu Ruth He, Mallory Makowsky, Di Ran, Alejandra Negro, Ghassan K. Abou‐Alfa